EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study

Shelby E Meier, Michael B Orr, Matthew S Shotwell, Rebecca N Jerome, Jana K Shirey-Rice, Jill M Pulley, David A Edwards, Amanda D Toye, Puneet Mishra, Tigran Kesayan iD

Pain Medicine · 2025

DOI: 10.1093/pm/pnaf054 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, 2025. Verfasst von Shelby E Meier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN 37203-8820, United States. Hauptthemen laut MEDLINE: Guanfacine, Trigeminal Neuralgia, Nerve Block, Adrenergic alpha-2 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, CTSA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trigeminal neuralgia and painful trigeminal neuropathy are severely painful conditions which are often difficult to treat with medications. A Phenome-Wide Association Study (PheWAS) analysis identified an association between single-nucleotide variants in the alpha-2 adrenergic receptor (ADRA2) subtype B, a G protein-coupled receptor expressed on peripheral and central presynaptic terminals, and an increased risk for trigeminal nerve disorders. We hypothesized that adding the ADRA2 agonist guanfacine to routine care trigeminal nerve injections would provide enhanced pain relief in trigeminal neuralgia than routine care alone.

Methods

PheWAS analysis identified the drug target/indication pair. The trial was a single-center, prospective, randomized, controlled, double-blinded, 2-way crossover trial for patients with pain attributed to the trigeminal nerve. Injections of lidocaine alone or lidocaine + 250 µg guanfacine were delivered to the V2 and V3 branches of the trigeminal nerve by experienced clinicians. Patients reported pain using a Numeric Rating Scale (NRS) and quality of life measures (using the PROMIS Global Physical Health, Mental Health, and Pain Interference surveys).

Results

NRS pain scores over the first 8 h post-injection were significantly lower in the interventional group (guanfacine + lidocaine) compared to active control (P < .001), but not from day 1 through day 14. There was no significant difference between treatment groups in time to recovery of baseline pain intensity (primary outcome), PROMIS outcomes, or adverse events (AEs). No serious AEs were reported.

Conclusions

The addition of 250 µg guanfacine to lidocaine for a nerve block procedure enhanced analgesia compared to lidocaine alone within the first 8 h post-injection. Clinical Trial Number NCT03865940, https://clinicaltrials.gov/study/NCT03865940

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GuanfacineTrigeminal NeuralgiaNerve BlockAdrenergic alpha-2 Receptor AgonistsPain ManagementTrigeminal NerveHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedProspective StudiesCross-Over StudiesAdultLidocaineAnesthetics, LocalPain Measurement

Stichwörter der Autor:innen

drug repurposingguanfacinenerve blockneuropathic paintrigeminal neuralgia

Substanzen

GuanfacineAdrenergic alpha-2 Receptor AgonistsLidocaineAnesthetics, Local

Autor:innen und Institutionen

  • Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN 37203-8820, United States.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37203-1741, United States.
  • Division of Pain Medicine, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37204, United States.
  • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.

ORCID-Profile: Tigran Kesayan

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • CTSA
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Meier, S. E., Orr, M. B., Shotwell, M. S., Jerome, R. N., Shirey-Rice, J. K., Pulley, J. M., Edwards, D. A., Toye, A. D., Mishra, P., & Kesayan, T. (2025). Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study. Pain Medicine. https://doi.org/10.1093/pm/pnaf054

Vancouver

Meier SE, Orr MB, Shotwell MS, Jerome RN, Shirey-Rice JK, Pulley JM, et al. Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study. Pain Medicine. 2025. doi:10.1093/pm/pnaf054

BibTeX
@article{Meier2025,
  author = {Meier, Shelby E and Orr, Michael B and Shotwell, Matthew S and Jerome, Rebecca N and Shirey-Rice, Jana K and Pulley, Jill M and Edwards, David A and Toye, Amanda D and Mishra, Puneet and Kesayan, Tigran},
  title = {Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study},
  journal = {Pain Medicine},
  year = {2025},
  doi = {10.1093/pm/pnaf054}
}
Kostenlos starten →